BridgeBio Pharma, Inc. (BBIO)

From the record

BridgeBio Pharma, Inc.'s filings since 2018 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

BridgeBio Pharma, Inc.'s 7 filed years say what it did: revenue went from $41 million in fiscal 2019 to $502 million in fiscal 2025, up 52.1% a year; it rose in 4 of 6 years; the deepest fall was 88% from fiscal 2022 to fiscal 2023; net income was positive in 0 of 7 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, BridgeBio Pharma, Inc.'s shareholders' equity was below zero, so the profit on it is not read, and gross profitability: its products earned about 51 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 323 cents per dollar of assets, and net share issuance: its share count grew 2.9% over the year (the filed statements).

From the record

BridgeBio Pharma, Inc.'s standing among 315 graded names in its industry family: revenue of $502 million in fiscal 2025 ranks in the top 19% by size; a net margin of -146% ranks in the top 50%; revenue growth of 86.3% a year over the last 3 filed years ranks in the top 16% (its annual reports).

From the record

BridgeBio Pharma, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Kumar, Neil (Chief Executive Officer, as filed), filing under that title since 2019-06-27, 7.4 years (top 28% of its family); the 16 officers and directors filing in the last fifteen months have been on the record a median of 6.6 years (top 33%); 3 officer or director changes were reported on Form 8-K since 2023-11-13, against the 16 people in charge now (top 15%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

BridgeBio Pharma, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $570 million against debt of $2.0 billion leaves -153.5% of its assets as net cash, bottom 1% of its family; cash from operations less capital spending is -89% of revenue (top 49%); a gross margin of 95.8% (top 7%); research spending of 90% of revenue (bottom 48%) (its annual report).

From the record

BridgeBio Pharma, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 86.3% a year over the last three filed years against 52.1% over all 7, speeding up (top 12% of its family); the newest year grew 126.4% (top 14%); research spending grew 4.2% a year (top 47%); capital spending grew -38.9% a year (bottom 31%) (its annual reports). BridgeBio Pharma, Inc. reported 3 product lines in fiscal 2025: Product at $362 million (72%), License and Service at $128 million (26%), Royalty at $11 million (2%); 2 of 3 grew against the year before (its annual report).

From the record

BridgeBio Pharma, Inc.'s newest year against its own record: revenue of $502 million in fiscal 2025 came in 33.9% above the $375 million its prior three years' pace pointed to (top 22% of its family); net income of $733 million against a prior three-year average of $560 million (bottom 30%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 12%) (its annual reports).